Stocktoria
10x Genomics, Inc. TXG
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2019-09-12
10x Genomics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M | $490.5M |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M |
| SG&A expense | $316.1M | $344.3M | $343.3M | $298.3M | $257.6M |
| Operating income | -$61.0M | -$194.6M | -$265.3M | -$167.9M | -$52.3M |
| Interest expense | — | — | $33,000 | $476,000 | $866,000 |
| Income tax | $3.6M | $4.9M | $6.3M | $4.0M | $4.5M |
| Net income | -$43.5M | -$182.6M | -$255.1M | -$166.0M | -$58.2M |
| EPS (diluted) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 |
| Operating cash flow | $136.1M | $6.7M | -$15.2M | -$33.6M | -$21.4M |
| Free cash flow | $130.1M | -$5.7M | -$63.8M | -$165.3M | -$122.7M |
| Cash & equivalents | — | $344.1M | $359.3M | $219.7M | $587.4M |
| Inventory | $56.3M | $83.1M | $73.7M | $81.6M | $60.0M |
| Total assets | $1.0B | $918.6M | $965.1M | $1.0B | $1.0B |
| Total liabilities | $245.0M | $208.5M | $224.1M | $223.2M | $201.3M |
| Shareholders' equity | $796.3M | $710.1M | $741.0M | $805.7M | $817.6M |
Source: SEC EDGAR filings · CIK 0001770787 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.